The concentration of heparin in plasma was measured using a chromogenic substrate. It appeared that the measurement of heparin concentration in plasma was important in therapeutic control and evaluation of heparin. There was a correlation between the activated partial thromboplastin time (APTT) and heparin concentration in plasma, but since the gradients of regression line differed in each of the cases, measurement of APTT alone would give a different estimate of heparin concentration in each case. Fibrinopeptide A (FPA) is considered as the best indicator for evaluation of therapeutic effects of heparin. Therapeutic heparin concentrations were defined as ranging from 0.2 to 1.2 IU/ml because the normalization of FPA was observed and there happened no hemorrhagic accidents in that range.
types of assay for heparin hitherto have been used. These include whole blood clotting time and activated partial thromboplastin time (APTT) (Godal,1) Teien and Abildgaard6)). Although both of these assays are relatively insensitive to heparin but reflect the overall influence of the anticoagulative activities on whole blood or plasma, the sensitivity of APTT differs by the order of magnitude from that of the whole blood clotting time, as pointed out by Godal.1) The point about APTT is that, unlike anti-Xa assay, it is considerably influenced by the levels of other clotting factors, especially in patients with thrombotic disease, and is therefore unreliable as a measure of heparin concentration. Direct determination of plasma heparin concentration was, therefore, done and effectiveness of various routine clinical tests as an indicator of heparin effect was evaluated in the present article.
METHODS

Measurement of heparin in plasma
As shown in Fig. 1 , standard curves were prepared using standard heparin dilution, antithrombin III (AT III), factor Xa (FXa), and a chromogenic substrate (S-2222; Bz-Ile-Glu(r-OR)-Gly-Arg-p Nitroanyline-HCl) (KABI Co). The heparin concentration was calculated from the absorbance for platelet poor plasma prepared from patients' blood and the standard curves as described by Teien.6),7) 2. Measurement of fibrinopeptide A (FPA) FPA was measured by the FPA radioimmunoassay kit (IMUCO Co) as de- the standard curves prepared with the same kind of heparin used actually for the treatment were used for the measurement of heparin concentration. When the p-nitroanyline (PNA) concentration is plotted on the ordinate and heparin concentration on the abscissa, the regression line of the standard curve for Japanese Pharmacopoeia heparin was Y=-0.540X+0.890. The coefficient of correlation of the measured values was r=-0.9908, which was significant at p<0.001 (Fig. 2) . While the therapeutic range of heparin was defined as 0.1-0.7IU/ml by Teien and Abildgaad with the polybrane titration method,6) the range of 0.2-1.2IU/ml was considered, using a chromogenic substrate, to be effective and safe in our cases.
2. Investigation of clinical cases during heparin therapy a) 37-year-old, male, acute respiratory distress syndrome (ARDS) with DIC (Case 1 in DIC group) Jap. Heart J. May, 1980 begun intravenously and subcutaneously. FPA improved immediately after the use of heparin and a decrease of FDP followed thereafter. Then, after a little while, fibrinogen and the other coagulation-fibrinolytic factors became normal and DIC was improved (Fig. 6 ). e) 59-year-old, woman, right deep vein thrombosis (Case 4 in non-DIC group) The patient was operated on for cholelithiasis on November 28, 1978 and was attacked by sudden right chest pain and cough on December 16, which were followed by spontaneous remission in a few days. Then she was attacked by the pain and swelling of the right lower extremity on January 17 1979. On admission, it was demonstrated by chest X-ray and scintillation scans of the lung that S9 of the right lung had been suffered from infarction. Case 6: male, rt. femoral artery thrombosis rin were near the maximum level of the therapeutic range defined by Teien and Abildgaard, recurrent thrombotic episodes were seen and FPA was elevated at that time. After the third fibrinolytic therapy, FPA was stabilized in normal range and the patient got well, while the other coagulation-fibrinolytic factors remained abnormal for several days or weeks thereafter. During the treatment, slight subcutaneous bleedings were seen when the concentration of plasma heparin rose above 1.8IU/ml (Fig. 7) . f) Correlation between heparin concentration and APTT in patients without DIC When APTT and heparin concentration in these cases were plotted on because the patient was in shock, and there were disturbance of peripheral circulation and continuous oozing. Therefore, it is suggested that an intravenous drip of heparin is desirable in patients with shock. APTT has been widely used as a guide for control of heparin level.
There was a correlation between concentration of heparin in plasma and APTT, and such correlation was recognized also in DIC cases, in which heparin was effective. However, when the regression lines were compared among patients, the gradients were not always similar but differed among them. Therefore, even when APTT was at the same level, the heparin concentration was not always the same. Then, regression line of APTT-heparin correlation should be prepared by measuring APTT in the mixture solution of heparin and preheparin plasma from each patient, when APTT is used as the control index. The concentration of heparin in plasma should be estimated from the regression line and APTT of patient after heparin administration. There is a major possibility that the heparin control method only using APTT may lead to critical hemorrhages and sufficient therapeutic results may not be obtained.
In connection with AT III, a heparin co-factor, it has been pointed out that AT III level may decrease markedly during thrombotic episodes.8) Either heparin or AT III may be rate limiting in the inhibition of thrombin, and more heparin is required for the same antithrombotic effect when AT III level in plasma is depressed.8) Among our patients, including those with DIC, the lowest value of AT III was 15mg/100ml. This patient was an ARDS case, in which heparin was effective. Further investigations are planned for cases with low AT III levels.
The results in 12 cases suggest that FPA is more sensitive indicator of thrombin action than FDP, Fibrinogen, AT III, platelet counts, and the other factors and provides direct information concerning the effectiveness of heparin treatment in preventing fibrin formation.
